NBIX - Neurocrine Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600

Full Time Employees700

Key Executives

NameTitlePayExercisedYear Born
Dr. Kevin C. GormanCEO & Director1.15M22.04M1958
Mr. Matthew C. AbernethyChief Financial Officer689.24kN/A1981
Mr. Kyle W. GanoChief Bus. Devel. and Strategy Officer602.64k4.93M1973
Mr. Eric S. BenevichChief Commercial Officer676.85kN/A1965
Ms. Eiry Wyn RobertsChief Medical Officer1.39MN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Neurocrine Biosciences, Inc. discovers and develops treatments for patients with neurological, endocrine, and psychiatric disorders. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of adults with tardive dyskinesia; and ORILISSA (elagolix) for the management of moderate to severe endometriosis pain in women in the United States. It also develops opicapone, a catechol-o-methyltransferase inhibitor, for the treatment of Parkinson's disease patients; crinecerfont for the treatment of congenital adrenal hyperplasia; and NBIb-1817, an investigational gene therapy for the treatment of Parkinson's disease. In addition, the company is developing NBI-921352, an inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy; and ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for potential use in certain forms of generalized epilepsy. Neurocrine Biosciences, Inc. has collaboration agreements with AbbVie Inc.; Mitsubishi Tanabe Pharma Corporation; BIAL – Portela & Ca, S.A.; Jnana Therapeutics Inc.; Voyager Therapeutics, Inc.; and Xenon Pharmaceuticals Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Corporate Governance

Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.